Medical Management of Obesity: Current Trends and Future Perspectives.

Q2 Medicine
Methodist DeBakey cardiovascular journal Pub Date : 2025-02-18 eCollection Date: 2025-01-01 DOI:10.14797/mdcvj.1503
Andres Calderon Valladares, Maria Aguilera Astudillo, Alexsandra Rojas Drinnon, Samaneh Dowlatshahi, Abhishek Kansara, Jawairia Shakil, Bhargavi Patham
{"title":"Medical Management of Obesity: Current Trends and Future Perspectives.","authors":"Andres Calderon Valladares, Maria Aguilera Astudillo, Alexsandra Rojas Drinnon, Samaneh Dowlatshahi, Abhishek Kansara, Jawairia Shakil, Bhargavi Patham","doi":"10.14797/mdcvj.1503","DOIUrl":null,"url":null,"abstract":"<p><p>Obesity and overweight have become increasingly significant conditions, affecting more than 70% of the adult population in the United States. These conditions are caused by a combination of factors, including genetic, behavioral, environmental, and medical influences. Obesity is a major risk factor for cardiovascular and metabolic diseases. A comprehensive treatment plan for individuals with obesity must recognize the chronic nature of the condition and offer strategies for weight reduction and long-term cardiometabolic benefits. Over the past several decades, multiple therapeutic options have been implemented to address weight loss, appetite regulation, and caloric expenditure, with the goal of reducing the burden of obesity and improving cardiovascular outcomes. Pharmacological treatment of obesity has focused primarily on the central regulation of appetite and food intake behavior. The introduction of incretin agonists for obesity treatment has ushered in a new era of cardiometabolic health, with a multitargeted mechanism that achieves weight loss, glycemic control, decreased cardiovascular mortality, and other metabolic benefits. This review explores the current pharmacological options and the future of obesity treatment.</p>","PeriodicalId":39207,"journal":{"name":"Methodist DeBakey cardiovascular journal","volume":"21 2","pages":"62-73"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844017/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Methodist DeBakey cardiovascular journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14797/mdcvj.1503","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Obesity and overweight have become increasingly significant conditions, affecting more than 70% of the adult population in the United States. These conditions are caused by a combination of factors, including genetic, behavioral, environmental, and medical influences. Obesity is a major risk factor for cardiovascular and metabolic diseases. A comprehensive treatment plan for individuals with obesity must recognize the chronic nature of the condition and offer strategies for weight reduction and long-term cardiometabolic benefits. Over the past several decades, multiple therapeutic options have been implemented to address weight loss, appetite regulation, and caloric expenditure, with the goal of reducing the burden of obesity and improving cardiovascular outcomes. Pharmacological treatment of obesity has focused primarily on the central regulation of appetite and food intake behavior. The introduction of incretin agonists for obesity treatment has ushered in a new era of cardiometabolic health, with a multitargeted mechanism that achieves weight loss, glycemic control, decreased cardiovascular mortality, and other metabolic benefits. This review explores the current pharmacological options and the future of obesity treatment.

Abstract Image

肥胖的医学管理:当前趋势和未来展望。
肥胖和超重已经成为越来越重要的疾病,影响着美国70%以上的成年人。这些情况是由多种因素引起的,包括遗传、行为、环境和医学影响。肥胖是心血管和代谢疾病的主要危险因素。针对肥胖患者的综合治疗计划必须认识到这种疾病的慢性性质,并提供减轻体重和长期心脏代谢益处的策略。在过去的几十年里,已经实施了多种治疗方案来解决体重减轻、食欲调节和热量消耗问题,目的是减轻肥胖负担并改善心血管疾病的预后。肥胖的药理治疗主要集中在食欲和食物摄入行为的中枢调节上。肠促胰岛素激动剂用于肥胖治疗,开启了心脏代谢健康的新时代,具有多靶点机制,可实现减肥、血糖控制、降低心血管死亡率和其他代谢益处。这篇综述探讨了目前的药物选择和肥胖症治疗的未来。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.30
自引率
0.00%
发文量
65
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信